Standards of care in mesothelioma treatment.

Szczegóły
Abstrakt

Tytuł:: Standards of care in mesothelioma treatment.
Autorzy:: Harden SV; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. .
Darlison L; University Hospitals of Leicester, Leicester, UK.
Beckett P; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
Bibby AC; Academic Respiratory Unit, Bristol University, Bristol, UK.
Źródło:: British journal of cancer [Br J Cancer] 2020 Nov; Vol. 123 (11), pp. 1588-1589. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
MeSH Terms:: Standard of Care*
Medical Oncology/*standards
Mesothelioma/*therapy
Humans ; United Kingdom
References:: Cancer Research UK. Mesothelioma Statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/mesothelioma . Accessed April 2020.
Royal College of Physicians. National Mesothelioma Audit report 2020 (for the audit period 2016–18). (Royal College of Physicians, London, 2020).
NHS England. 2013/14 NHS STANDARD CONTRACT FOR CANCER: MALIGNANT MESOTHELIOMA (ADULT). (NHS England B10/S/a, 2013).
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003). (PMID: 10.1200/JCO.2003.11.136)
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405–1414 (2016). (PMID: 10.1016/S0140-6736(15)01238-6)
Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J. et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 12, 763–772 (2011). (PMID: 10.1016/S1470-2045(11)70149-8)
Clive, A. O., Taylor, H., Dobson, L., Wilson, P., de Winton, E., Panakis, N. et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 17, 1094–1104 (2016). (PMID: 10.1016/S1470-2045(16)30095-X)
Bayman, N., Appel, W., Ashcroft, L., Baldwin, D. R., Bates, A., Darlison, L. et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial. J. Clin. Oncol. 37, 1200–1208 (2019). (PMID: 10.1200/JCO.18.01678)
Woolhouse, I., Bishop, L., Darlison, L., De Fonseka, D., Edey, A., Edwards, J. et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73, i1–i30 (2018). (PMID: 10.1136/thoraxjnl-2017-211321)
Royal College of Physicians, Mesothelioma UK. National Mesothelioma Audit organisational audit report 2019. (Royal College of Physicians, London, 2020).
Entry Date(s):: Date Created: 20200922 Date Completed: 20210318 Latest Revision: 20210923
Update Code:: 20240105
PubMed Central ID:: PMC7686349
DOI:: 10.1038/s41416-020-01078-y
PMID:: 32958826
: Czasopismo naukowe

The UK has the highest incidence of mesothelioma in the world, but services vary across the country partly due to uneven geographical distribution of cases. The Mesothelioma UK-funded national organisational audit has highlighted challenges in accessing diagnostic procedures such as thoracoscopy, as well as identifying examples of best practice, including access to clinical trials and specialist therapeutic procedures. To ensure equitable and optimal patient care, cancer alliances should have established referral pathways to specialist multidisciplinary team (MDT) services for discussion of all mesothelioma patients.

Informacja